Shiroyama, Mamiko
Fukuoka, Shota
Masuishi, Toshiki
Takashima, Atsuo
Kumekawa, Yosuke
Kajiwara, Takeshi
Yamazaki, Kentaro
Shimada, Yasuhiro
Esaki, Taito
Makiyama, Akitaka
Moriwaki, Toshikazu
Article History
Received: 21 June 2023
Accepted: 17 October 2023
First Online: 20 October 2023
Competing interests
: Toshiki Masuishi received honoraria from Taiho. Atsuo Takashima received honoraria from Eli Lilly, Ono, Taiho, Takeda, and Chugai, and received research funding from Daiichi, Ono, Bristol Myers, and MSD. Takeshi Kajiwara received lecture fees from Eli Lilly, Chugai, and Bristol-Myers Squibb. Kentaro Yamazaki received honoraria from Chugai, Takeda, Yakult, Taiho, Daiichi Sankyo, Bayer, Merck Serono, Eli Lilly, Sanofi, Ono, MSD, and Bristol Myers, and research funding from Taiho. Taito Esaki received honoraria from Chugai, Daiichi Sankyo, Taiho, and research funding from Daiichi Sankyo, Chugai, Amgen, Ono, Pfizer, Novartis, Astellas, Astellas Amgen Biopharma, Quintiles, AsahikaseiPharma, Syneos Health, and IQVIA. Akitaka Makiyama received honoraria from Eli Lilly, Taiho, Ono, Bristol-Myers Squibb, and Daiichi Sankyo. All other authors declare no potential conflict of interest.